GSA Capital Partners LLP Invests $67,000 in Gossamer Bio, Inc. (NASDAQ:GOSS)

GSA Capital Partners LLP purchased a new stake in shares of Gossamer Bio, Inc. (NASDAQ:GOSS) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 67,546 shares of the company’s stock, valued at approximately $67,000.

Other institutional investors also recently bought and sold shares of the company. Sequoia Financial Advisors LLC boosted its position in Gossamer Bio by 27.2% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 93,500 shares of the company’s stock valued at $84,000 after acquiring an additional 20,000 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Gossamer Bio in the 1st quarter valued at approximately $34,000. Financial Advocates Investment Management boosted its position in shares of Gossamer Bio by 57.5% during the second quarter. Financial Advocates Investment Management now owns 106,850 shares of the company’s stock valued at $96,000 after purchasing an additional 39,000 shares in the last quarter. US Bancorp DE purchased a new stake in Gossamer Bio in the third quarter worth $39,000. Finally, Choreo LLC bought a new position in Gossamer Bio in the second quarter worth $46,000. 81.23% of the stock is owned by institutional investors.

Gossamer Bio Stock Performance

NASDAQ GOSS opened at $0.70 on Tuesday. Gossamer Bio, Inc. has a 12 month low of $0.50 and a 12 month high of $1.60. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 3.64. The stock’s fifty day moving average price is $0.91 and its 200-day moving average price is $0.86. The stock has a market cap of $158.44 million, a P/E ratio of -2.17 and a beta of 1.96.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.04. The firm had revenue of $9.48 million for the quarter, compared to analysts’ expectations of $4.52 million. As a group, equities analysts forecast that Gossamer Bio, Inc. will post -0.28 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on GOSS shares. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Gossamer Bio in a report on Monday, November 11th. Wedbush reissued an “outperform” rating and set a $4.00 price objective on shares of Gossamer Bio in a research note on Tuesday, August 13th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $9.20.

Gossamer Bio Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.